PRWeb The Leader Press Release Distribution
See How PRWeb Works

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for March 8, 2003 Subscribe to this News Feed    
 

Geneva Bioinformatics (GeneBio) S.A. Launches a Novel Version of The 2-D Gel Analysis Software, Melanie

Latest Version of the 2-D Electropheresis software, Melanie 4 now avaliable through Geneva Bioinformatics S.A.

Geneva, Switzerland -- Geneva Bioinformatics (GeneBio) S.A. has announced the release of Melanie 4, the newest version of Melanie 2-D gel analysis software. A flexible and modern software package, Melanie 4 provides researchers with new innovative features adaptable to their needs in 2-D gel analysis.

Prof. Ron Appel, Co-founder and Chairman of the executive board of the Swiss Institute of Bioinformatics (SIB), head of the Proteome Informatics Group and creator of Melanie at the SIB states, We are very pleased to provide such an advanced and unlimited but customisable 2-D gel analysis software to the research community. 2D-PAGE remains a key technology in the exciting field of proteomics. At the SIB we are very keen on performing high quality applied research in order to provide the community with the appropriate solutions to their protein analysis problems. With the prolonged recognition and experience of the SIB in the bioinformatics and proteomics fields, Melanie 4 will prove to be the next generation software in 2-D gel analysis"

Mr. Nasri Nahas, CEO of GeneBio states: This is the latest addition to our product portfolio, aimed to raise the information barrier in 2-D gel analysis. We believe Melanie 4 is an integral part of proteomics study and feel that GeneBio has an important part to play in this arena. As the proteomics field grows, GeneBio continues to endeavour in making knowledge more readily available and committing all our development efforts to breaking the information bottleneck".

New Technology Encourages Progression
Take the Next Step

Melanie 4 is the latest generation of the well-known 2-D electrophoresis analysis software package. Developed by the SIB, Melanie is continuously improved and enhanced based on feedback from users and the real-life problems experienced by biologists and proteomics scientists from Prof. Hochstrasser's group at the Geneva University Hospital, as well as specialists from other reputed research institutes.

Melanie 4 is conceived to extract pertinent information from the analysis of 2-D electrophoresis gels, providing an efficient approach to protein profiling and an accurate visual basis for proteome comparisons. The software has an efficient design and innovative functions addressing the needs of both experts and beginners. Melanie can handle large volumes of 2-DE data and its interactive gel analysis steps can easily be automated through the use of customisable scripts, exploitable on any dataset. Powerful data management tools and visualisation aids (dual channel display, 3-D view, intensity profiles) have been integrated, while its open architecture based on XML standard and exports to automated spot pickers allow a seamless integration of Melanie into any laboratory workflow.
For more information about Melanie or to download your free demo version please go to http://www.genebio.com/melanie.

GENEVA BIOINFORMATICS (GENEBIO) S.A.

Founded in 1997, GeneBio is a multifaceted bioinformatics company offering its clients original solutions for shaping heterogeneous information into relevant biological knowledge. For more information about GeneBio, please visit: www.genebio.com

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Alistair Blair-davies
Geneva Bioinformatics S.a.
+41 22 702 99 00
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appears here.